Company: AGIO
Filing Date: 2025-05-01
Form Type: 10-Q
Source: 0001439222-25-000036
Chunk: 67

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-05-01
Form: 10-Q
Item: Part I, Item 1
Chunk 67
---
,883 — — — 1,883 Common stock issued under stock incentive plan and ESPP730,496 1 1,618 — — — — 1,619 Stock-based compensation expense— — 11,359 — — — — 11,359 Net loss— — — — (89,289)— — (89,289)Balance at March 31, 202574,103,192 $74 $2,506,788 $365 $(238,213)(16,216,411)$(802,486)$1,466,528 

Common StockAdditionalPaid-InCapitalAccumulatedOtherComprehensiveLossAccumulatedDeficitTreasury StockTotalStockholders’Equity(in thousands, except share amounts)SharesAmountSharesAmountBalance at December 31, 202372,161,489 $72 $2,436,523 $(441)$(822,649)(16,216,411)$(802,486)$811,019 Unrealized loss on available-for-sale securities— — — (646)— — — (646)Common stock issued under stock incentive plan and ESPP806,433 1 5,863 — — — — 5,864 Stock-based compensation expense— — 9,234 — — — — 9,234 Net loss— — — — (81,549)— — (81,549)Balance at March 31, 202472,967,922 $73 $2,451,620 $(1,087)$(904,198)(16,216,411)$(802,486)$743,922 

See accompanying Notes to Condensed Consolidated Financial Statements.

4

AGIOS PHARMACEUTICALS, INC.Condensed Consolidated Statements of Cash Flows(Unaudited)Three Months EndedMarch 31,(In thousands)20252024Operating activitiesNet loss$(89,289)$(81,549)Adjustments to reconcile net loss from operations to net cash used in operating activities:Depreciation and amortization1,278 1,348 Stock-based compensation expense11,359 9,234 Net accretion of discount on marketable securities(1,348)(2,527)Gain on disposal of property and